Term ends Jan 4, 2034 · High confidence
20-year base term ends Jul 10, 2033
Held by Bioverativ Therapeutics Inc.
Filed Jan 9, 2015 as application 14/413,765 · Granted Nov 27, 2018
Base term plus 178 days of patent term adjustment (USPTO delay)
Today
2013
2034
Clock starts
Jul 10, 2013
Jul 10, 2013
Term ends
Jan 4, 2034
Jan 4, 2034
Granted
Nov 27, 2018
Nov 27, 2018
base term
patent term adjustment
fee events
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
178
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 11,370,827, to Jan 4, 2034. The term already ends on or before that date, so the cap shortened nothing.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
4
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term runs 178 days past its 20-year base term on prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 2 of 3 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jul 10, 2013, when application PCT/US2013/049989, the earliest non-provisional in its chain, was filed (this one was filed Jan 9, 2015) | Jul 10, 2033 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +178 days, USPTO patent term adjustment record | Jan 4, 2034 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 11,370,827) | resolves to Jan 4, 2034, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jan 4, 2034 | High confidence |
This family
| Application PCT/US2013/049989 | PCT application no patent term | no patent term |
| US 10,138,291 | this patent Jan 2034 | Jan 2034 |
| US 11,091,534 | In force Jul 2033 | Jul 2033 |
| Application 17/358,142 | Pending not computed | not computed |
Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| May 4, 2015 Reel 35571, frame 926 | Biogen Idec Ma Inc. | Biogen Ma Inc. | Change of Name |
| Apr 12, 2016 Reel 38257, frame 346 | Chhabra, Ekta Seth; Liu, Tongyao; Peters, Robert T.; Kulman, John | Biogen Ma Inc. | Assignment of Assignor's Interest |
| Apr 13, 2016 Reel 38270, frame 669 | Chang, Pei-yun | Amunix Operating Inc. | Assignment of Assignor's Interest |
| Feb 26, 2017 Reel 41818, frame 802 | Biogen Ma Inc. | Bioverativ Therapeutics Inc. | Assignment of Assignor's Interest |
| Jun 27, 2018 Reel 46212, frame 249 | Amunix Operating Inc. | Bioverativ Therapeutics Inc. | Assignment of Assignor's Interest |
| Aug 22, 2018 Reel 46661, frame 491 | Amunix Operating Inc. | Bioverativ Therapeutics Inc. | Assignment of Assignor's Interest |
| Sep 17, 2021 Reel 57515, frame 973 | Jiang, Haiyan | Biogen Ma Inc. | Assignment of Assignor's Interest |
| Sep 17, 2021 Reel 57517, frame 280 | Biogen Ma Inc. | Bioverativ Therapeutics Inc. | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Jan 2034
Term ends Jan 4, 2034. Maintenance fees still fall due before then
Note
The 178 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 11,370,827, ends no earlier than this term, so it caps nothing.
Citations
38
later US patents cite this one
That is top 10% of utility patents granted in 2018 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.